Corpus ID: 30997934

Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers.

  title={Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers.},
  author={A. Pargal and S. Rani},
  journal={The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease},
  volume={5 1},
  • A. Pargal, S. Rani
  • Published 2001
  • Medicine
  • The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
OBJECTIVE To characterise the pharmacokinetics of rifampicin (RMP) in healthy Asian Indian volunteers after oral administration of commercially marketed reference formulations. DESIGN Two separate studies were conducted. In Study 1, 12 volunteers were administered a single 450 mg sugar-coated tablet, and in Study 2, 11 volunteers were administered a 30 ml suspension (100 mg/5 ml) equivalent to a 600 mg dose of RMP. Blood samples were collected at 0 hours and then at 0.25, 0.5, 0.75, 1, 1.5, 2… Expand
Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis Patients
Investigating the effect of a higher dose of rifampin in terms of pharmacokinetics and tolerability found that increasing the dose was associated with a more than dose-proportional increase in the mean AUC0-24 and Cmax of r ifampin without affecting the incidence of serious adverse effects. Expand
The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children.
It is indicated that for equivalent RMP dosages adult patients reach a lower C(max) than adult volunteers and that adults, both volunteers and patients established on RMP reach higher C( max) values than children; children established on rifampicin require approximately twice the mg/kg body weight dosage of RMP to reach serum concentrations equivalent to those of adults. Expand
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
Simulations based on models suggest that children will receive adequate rifampicin exposures when compared with adults, but with a larger degree of variability, however, pyrazinamide and isoniazid exposures in many children will be lower than in adults. Expand
Lack of Enzyme‐Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide
The pharmacokinetics of enfuvirtide are not induced by a 10‐day pretreatment with rifampicin, and there were no unexpected effects of rifampsicin on the short‐term antiviral effect or safety of the administered antiretroviral treatment. Expand
Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis
It is encouraging that daily rifampicin doses up to 35 mg/kg were found to be safe and well-tolerated over a period of 12 weeks and high-dose rifampsicin should thus be considered in future studies when constructing potentially shorter regimens. Expand
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction
Simulations with doses of up to 35 mg/kg produced results closely in line with those of clinical trials, and the model predicts that increases in the dose of rifampin result in more-than-linear drug exposure increases as measured by the 24-h area under the concentration-time curve. Expand
Pharmacokinetics of Antituberculosis Drugs in Pulmonary Tuberculosis Patients with Type 2 Diabetes
It is concluded that diabetes does not alter the pharmacokinetics of antituberculosis drugs during the intensive phase of tuberculosis treatment, and the cause of increased tuberculosis treatment failure among diabetic patients is determined. Expand
Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs
The overall results suggest that the pulmonary concentrations obtained with the standard RIF dose are too low in most subjects, and supports the need to evaluate higher doses of RIF for the treatment of patients with tuberculosis. Expand
Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats
Results showed that Labrasol and Pluronic F68 might inhibit the function of P-gp in the intestine, thereby increasing intestinal absorption and changing the pharmacokinetic parameters of rifampicin. Expand
Insights into the pharmacokinetic properties of antitubercular drugs
This article provides a brief compilation of the information available regarding published pharmacokinetic data for anti-TB drugs and may act as a single window for investigators/medical practitioners in this field to achieve optimal results in patients. Expand